Solutia Reports Third Quarter 20...(--- --- Total Shareholder...)

Date:10/26/2009

--- --- Total Shareholders' Equity 609 529 --- --- Total Liabilities and Shareholders' Equity $3,208 $3,734 ====== ====== SOLUTIA INC. CONSOLIDATED STATEMENT OF CASH FLOWS (Dollars in millions) Successor Successor Predecessor --------- --------- ----------- Nine Months Seven Months Two Months Ended Ended Ended September 30, September 30, February 29, 2009 2008 2008 ------------- ------------- ------------ INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS OPERATING ACTIVITIES: Net income (loss) $(117) $(48) $1,454 Adjustments to reconcile net income (loss) to net cash provided by (used in) operations: Net income attributable to noncontrolling interest (3) (5) --- (Income) Loss from discontinued operations, net of tax 169 52 (204) Depreciation and amortization 78 64 11 Revaluation of assets and liabilities, net of tax --- --- (1,383) Discharge of claims and liabilities, net of tax --- --- 100 Other reorganization items, net --- --- 52 Pension obligation
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009